Zobrazeno 81 - 90
of 185
pro vyhledávání: '"Olivier Adotevi"'
Autor:
Olivier Adotevi, Benoit Lecoester, Jérémy Baude, Gilles Truc, Céline Mirjolet, Jihane Boustani, Charlène Latour
Publikováno v:
Cancers, Vol 13, Iss 4893, p 4893 (2021)
Cancers
Cancers
Simple Summary Although immune checkpoint blockade has yielded unprecedented and durable responses in cancer patients, the efficacy of this treatment remains limited. Radiation therapy can induce immunogenic cell death that contributes to the local e
Autor:
Valérie Doppler, Olivier Adotevi, Thierry Huet, Jacques Medioni, Claire Germain, Luis Augusto Teixeira, Caroline Laheurte, Marie Escande, Julie Garibal, Pierre Langlade Demoyen, Marie-Agnès Dragon-Durey, Maria Wehbe
Publikováno v:
Cancer Research. 81:CT021-CT021
Background INVAC-1 is an optimized DNA plasmid encoding an inactive form of human Telomerase Reverse Transcriptase (hTERT), a universal tumor antigen expressed in most of human tumors with little or no expression in normal somatic cells. Primary phar
Autor:
F. Aubin, Olivier Adotevi, Christophe Borg, Caroline Laheurte, Laura Boullerot, A. Renaudin, Charlée Nardin, Yann Godet, Eve Puzenat, E. Orillard
Publikováno v:
Annales de Dermatologie et de Vénéréologie. 147:A22-A23
La reponse immunitaire lymphocytaire T CD4 Th1 joue un role important dans l’immunite anti tumorale et a ete etudiee dans de nombreux cancers. Nous avons evalue la reponse immunitaire T CD4 Th1 grâce a la reponse T CD4 Th1 anti-telomerase (anti-TE
Autor:
Elodie Lauret Marie Joseph, Séverine Valmary-Degano, Romain Boidot, Jean-René Pallandre, Olivier Adotevi, Yann Godet, Mohamad Hamieh, Jean Baptiste Latouche, Christophe Borg, Talal Al Saati, Jeanne Galaine, L. Rangan, Afag Asgarova, Laurent Beziaud, Magalie Dosset, Julie Francoual
Publikováno v:
Oncotarget
Oncotarget, Impact journals, 2017, 8 (30), pp.48959-48971. ⟨10.18632/oncotarget.16900⟩
Oncotarget, 2017, 8 (30), pp.48959-48971. ⟨10.18632/oncotarget.16900⟩
Oncotarget, Impact journals, 2017, 8 (30), pp.48959-48971. 〈http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path=16900&pubmed-linkout=1〉. 〈10.18632/oncotarget.16900〉
Oncotarget, Impact journals, 2017, 8 (30), pp.48959-48971. ⟨10.18632/oncotarget.16900⟩
Oncotarget, 2017, 8 (30), pp.48959-48971. ⟨10.18632/oncotarget.16900⟩
Oncotarget, Impact journals, 2017, 8 (30), pp.48959-48971. 〈http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path=16900&pubmed-linkout=1〉. 〈10.18632/oncotarget.16900〉
IF 5.168; International audience; HLA-A*0201/DRB1*0101 transgenic mice (A2/DR1 mice) have been developed to study the immunogenicity of tumor antigen-derived T cell epitopes. To extend the use and application of this mouse model in the field of antit
Publikováno v:
Bulletin du Cancer. 103:S127-S131
Resume L’activation des lymphocytes T est un processus finement regule permettant de mettre en place une reponse immmunitaire anti-infectieuse ou antitumorale efficace tout en evitant des reactions auto-immunes deleteres. Bien que les lymphocytes T
Autor:
Philippe Barthélémy, Sophie Paget-Bailly, Stefano Kim, J.-C. Eymard, Amélie Anota, Antoine Thiery-Vuillemin, Hamadi Almotlak, Olivier Adotevi, Elsa Curtit, Virginie Westeel, Guillaume Mouillet, J. Fritzsch, N. Meneveau, O. Djoumakh, Tristan Maurina, Lionnel Geoffrois, Laura Mansi, Guillaume Eberst, Marine Jary
Publikováno v:
Annals of Oncology. 30:v729-v730
Background Routine Electronic Monitoring of HRQoL (REMOQOL) in daily clinical care with real-time feedback to physicians could help to manage treatment-related toxicities, to personalize supportive care, and to assess the treatment benefit from the p
Autor:
M. Ramseyer, Yann Godet, Laurie Spehner, T. Andre, S.-B. Kim, Olivier Adotevi, E. Francois, Elodie Klajer, Marine Jary, Romain Loyon, Bruno Buecher, Christophe Borg, Marie Kroemer, Angélique Vienot
Publikováno v:
Annals of Oncology. 30:v770-v771
Background Anal squamous cell carcinoma (SCCA) is associated with E6 and E7 oncoproteins encoded by human papillomavirus (HPV) 16. Addition of Docetaxel to 5-Fluorouracil plus Cisplatin (DCF) induces favorable disease control and complete remission r
Autor:
Charline Tirole, Reyhan Hasanova, Thierry Lecomte, Christophe Borg, Jean Paul Feugeas, Emeline Orillard, Julien Viot, Olivier Adotevi, Kamal Asgarov, Adeline Bouard, Angélique Vienot, Stefano Kim, Elise Colle, Olivier Bouché, Elodie Klajer, Marine Jary, Romain Loyon
Publikováno v:
International journal of cancerReferences. 147(7)
Angiopoietin-2 (ANGPT2) is a prognostic factor in metastatic colorectal cancer (CRC). Nevertheless, it remains to be elucidated which molecular characteristics make up the ANGPT2-related poor-prognosis CRC subset. Public transcriptomic datasets were
Autor:
Léa Paolini, Olivier Adotevi, Maud Charpentier, E Dupel, Agnès Fortun, Emilie Dupré, Catherine Rabu, Nathalie Labarrière, Céline Beauvillain, L. Rangan, Jean-Baptiste Latouche, François Lang, Laetitia Florenceau
Publikováno v:
OncoImmunology
OncoImmunology, Taylor & Francis, 2019, 8 (4), pp.e1560919. ⟨10.1080/2162402X.2018.1560919⟩
OncoImmunology, Taylor & Francis, 2019, pp.e1560919-2. ⟨10.1080/2162402x.2018.1560919⟩
Oncoimmunology
OncoImmunology, Vol 8, Iss 4 (2019)
OncoImmunology, 2019, pp.e1560919-2. ⟨10.1080/2162402x.2018.1560919⟩
OncoImmunology, Taylor & Francis, 2019, 8 (4), pp.e1560919. ⟨10.1080/2162402X.2018.1560919⟩
OncoImmunology, Taylor & Francis, 2019, pp.e1560919-2. ⟨10.1080/2162402x.2018.1560919⟩
Oncoimmunology
OncoImmunology, Vol 8, Iss 4 (2019)
OncoImmunology, 2019, pp.e1560919-2. ⟨10.1080/2162402x.2018.1560919⟩
International audience; There is now a consensus that efficient peptide vaccination against cancer requires that peptides should (i) be exclusively presented by professional APC and (ii) stimulate both CD4 and CD8-specific T cell responses. To this a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbd5c6d1e4eb958168d0931139ddca4f
https://hal.archives-ouvertes.fr/hal-02131764/document
https://hal.archives-ouvertes.fr/hal-02131764/document
Autor:
Elodie Lauret Marie Joseph, Laura Boullerot, Françoise Le Pimpec-Barthes, Caroline Laheurte, Emilie Picard, Olivier Adotevi, Laurent Beziaud, Magalie Dosset, Jeanne Galaine, Christophe Borg, Virginie Westeel, Marion Jacquin, Béatrice Gaugler, Elizabeth Fabre, Romain Loyon, Laurie Spehner, Yann Godet, Guillaume Eberst, Anne Caignard
Publikováno v:
OncoImmunology, Vol 8, Iss 2 (2019)
Natural killer (NK) cells are innate effector lymphocytes widely involved in cancer immunosurveillance. In this study, we described three circulating NK cell subsets in patients with non-small cell lung cancer (NSCLC). Compared to healthy donors (HD)